Anzeige
Mehr »
Mittwoch, 11.02.2026 - Börsentäglich über 12.000 News
Breaking News: Pacifica meldet neue hochgradige Entdeckung und genau deshalb kann der Markt das nicht ignorieren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12CNT | ISIN: SE0003656834 | Ticker-Symbol: M02
Stuttgart
06.02.26 | 15:59
0,001 Euro
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
IZAFE GROUP AB Chart 1 Jahr
5-Tage-Chart
IZAFE GROUP AB 5-Tage-Chart
ACCESS Newswire
404 Leser
Artikel bewerten:
(2)

iZafe Group: Launch of Dosell Sales in Spain - A Groundbreaking Solution to Improve Medication Adherence

STOCKHOLM, SWEDEN / ACCESS Newswire / February 24, 2025 / iZafe Group (STO:IZAFE-B.ST) iZafe Group AB ("iZafe Group") proudly announces the sales launch of Dosell in Spain through a strategic partnership with Ti-Medi, a leading player in pharmaceutical technology in Southern Europe. The launch and commercialization of Dosell, under the brand name Savioo Home, mark a significant milestone in the effort to enhance medication adherence and improve the quality of life for patients with chronic diseases.

Dosell has already established itself as an effective solution in countries such as Sweden and the Netherlands, helping users take the right medication at the right time. Through the partnership with Ti-Medi, Dosell will now be available to the Spanish market, integrating with Ti-Medi's existing network of over 1,500 pharmacies that utilize their packaging technology for pre-dosed medications.
With Dosell, patients using Savioo Home will receive reminders to take their medication, and if they fail to do so on time, an automatic SMS alert will be sent to relatives or caregivers. This feature ensures a higher level of safety and security for both patients and their loved ones.

A Strategic Partnership for the Future
"We see tremendous potential in the Spanish market and are proud to launch Dosell through our collaboration with Ti-Medi. This is an important step in our international growth journey and our ambition to become a global leader in medication adherence," says Anders Segerström, CEO of iZafe Group.

"At Ti-Medi, we strive to provide technological solutions that simplify patients' lives and optimize the work of healthcare professionals. Savioo Home not only automates medication management at home but also enhances security for patients, relatives, and pharmacists. This enables more precise monitoring and better adherence to treatment. We believe that the future of healthcare lies in digitalization and tools that increase safety, convenience, and trust - and Savioo Home is a major step in that direction," Says Rafa Tibau, Pharmacist and Co-founder of Ti-Medi

About Ti-Medi
Ti-Medi is a pioneer in pharmaceutical technology in Southern Europe, serving more than 1,500 pharmacies with advanced packaging and dosing solutions. The company's mission is to enhance medication adherence and make healthcare more accessible and efficient. Read more at ti-medi.com

For more information about Savioo Home and how it can improve medication adherence and patient safety, visit the website savioo.com

Contacts

Anders Segerström, Chief Executive Officer
E-mail: anders.segerstrom@izafegroup.com
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
David Bagares gata 3
111 38 Stockholm

E-mail: ir@izafegroup.com
www.izafegroup.com
eucaps.com/izafe-group

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

The company leads the development of digital drug dispensing through the drug robot Dosell as well as the SaaS solution Pilloxa with the smart pillbox. The company's solutions reduce the risk of incorrect medication in the home, increase compliance, relieve public health care, increase the quality of life for patients and create a safer environment for relatives.

The customers consist of private individuals, pharmaceutical companies and public and private healthcare providers in Sweden, the Nordics and globally. iZafe Group primarily sells through well-established partners who already have long and deep customer relationships with the prioritized customer groups. The head office is in Stockholm.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

Image Attachments

SaviooHome

Attachments

Launch of Dosell sales in Spain - A groundbreaking solution to improve medication adherence

SOURCE: iZafe Group



© 2025 ACCESS Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.